| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b05d5871638d5180bb954591361c7635 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-35 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-35 |
| filingDate |
1984-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8ff99f9b7a53b3d16c20f8aa27170e1e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_653a977d331779e67e7e2992a0e3199d |
| publicationDate |
1985-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-8502616-A1 |
| titleOfInvention |
Treatment of metastasis |
| abstract |
A method for reducing the incidence of metastasis in tumor victims resides in the administration of forskolin or its analogs which are potent inhibitors of platelet aggregation. Forskoling compounds are generally defined as labdane diterpenoids having general formula (I). These compounds may be administered alone or in combination with other inhibitors of platelet aggregation. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0189801-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0293814-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0287469-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4724238-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2613935-A1 |
| priorityDate |
1983-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |